Confirmatory Study of BK1310 in Healthy Infants
Phase 3 Study of BK1310 Compared With ActHIB® and Tetrabik in Healthy Infants: A Randomized, Assessor-blind, Active-controlled
Sponsor: Tanabe Pharma Corporation
Listed as NCT03891758, this PHASE3 trial focuses on Bacterial Meningitis and Diphtheria and remains completed. Sponsored by Tanabe Pharma Corporation, it has been updated 13 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tanabe Pharma Corporation
- The Research Foundation for Microbial Diseases of Osaka University
For direct contact, visit the study record on ClinicalTrials.gov .